. Author manuscript; available in PMC: 2017 Sep 1.

Published in final edited form as: Curr Opin Urol. 2016 Sep;26(5):383–387. doi: 10.1097/MOU.0000000000000307

Table 1.

Summarized table highlighting frequent genomic alterations and possible actionable targets across the three classic renal cell carcinoma subtypes.

	Recurrent somatic mutations	Chromosomal copy number changes	Actionable targets
Clear cell renal cell carcinoma (ccRCC)(1, 7–11)	VHL, PBRM1, SETD2, BAP1, KDM5C, MTOR	Loss 3p and 14q, Gain 5q	MTOR, TSC1, TSC2
Papillary renal cell carcinoma (pRCC) (5, 12–14)	MET, SETD2, NF2, KDM6A, SMARCB1
Type 1	MET	Gain 7p and 17p	MET
Type 2	FH, CDKN2A
Chromophobe renal cell carcinoma (chRCC) (2, 12)	TP53, PTEN	Loss of 1, 2, 6, 10, 13, 17 and 21	PTEN